136 related articles for article (PubMed ID: 7763203)
1. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group.
McDermott MP; Jankovic J; Carter J; Fahn S; Gauthier S; Goetz CG; Golbe LI; Koller W; Lang AE; Olanow CW
Arch Neurol; 1995 Jun; 52(6):565-70. PubMed ID: 7763203
[TBL] [Abstract][Full Text] [Related]
2. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
3. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
[TBL] [Abstract][Full Text] [Related]
5. Effect of deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1989 Nov; 321(20):1364-71. PubMed ID: 2509910
[TBL] [Abstract][Full Text] [Related]
6. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Shoulson I
Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
[TBL] [Abstract][Full Text] [Related]
8. Freezing of gait in PD: prospective assessment in the DATATOP cohort.
Giladi N; McDermott MP; Fahn S; Przedborski S; Jankovic J; Stern M; Tanner C;
Neurology; 2001 Jun; 56(12):1712-21. PubMed ID: 11425939
[TBL] [Abstract][Full Text] [Related]
9. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees AJ
BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
[TBL] [Abstract][Full Text] [Related]
10. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
11. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1993 Jan; 328(3):176-83. PubMed ID: 8417384
[TBL] [Abstract][Full Text] [Related]
12. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1989 Oct; 46(10):1052-60. PubMed ID: 2508608
[TBL] [Abstract][Full Text] [Related]
13. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
Presthus J; Hajba A
Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
[TBL] [Abstract][Full Text] [Related]
14. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
[TBL] [Abstract][Full Text] [Related]
15. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
[TBL] [Abstract][Full Text] [Related]
16. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.
Elizan TS; Moros DA; Yahr MD
Arch Neurol; 1991 Jan; 48(1):31-4. PubMed ID: 1898848
[TBL] [Abstract][Full Text] [Related]
17. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
[TBL] [Abstract][Full Text] [Related]
18. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
19. Some new aspects of the effect of (-)deprenyl in Parkinson's disease--a retrospective study.
Málly J
J Neural Transm Park Dis Dement Sect; 1992; 4(2):155-64. PubMed ID: 1571079
[TBL] [Abstract][Full Text] [Related]
20. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group.
Shoulson I
Acta Neurol Scand Suppl; 1989; 126():171-5. PubMed ID: 2515723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
